Lazertinib
| Drug Information | |||
|---|---|---|---|
| Image | 250 | ||
| Identifiers
ATC Code
UNII ChEBI
|
Chemical Data
C H N O Molecular Weight | ||
Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). It is specifically designed to target the T790M mutation, a common resistance mutation that develops in patients treated with first- and second-generation EGFR inhibitors.
Mechanism of Action[edit | edit source]
Lazertinib works by selectively inhibiting the activity of mutant forms of the EGFR, including the T790M mutation, while sparing the wild-type EGFR. This selectivity helps to reduce the side effects associated with EGFR inhibition, such as skin rash and diarrhea, which are more common with earlier generation EGFR inhibitors.
Clinical Development[edit | edit source]
Lazertinib was developed by Yuhan Corporation and has undergone several clinical trials to evaluate its efficacy and safety in patients with NSCLC. In clinical studies, Lazertinib has shown promising results in terms of response rate and progression-free survival in patients with T790M-positive NSCLC who have progressed on prior EGFR TKI therapy.
Pharmacokinetics[edit | edit source]
Lazertinib is administered orally and has a favorable pharmacokinetic profile, with good bioavailability and a long half-life that supports once-daily dosing. It is metabolized primarily in the liver and excreted through both renal and fecal pathways.
Side Effects[edit | edit source]
Common side effects of Lazertinib include rash, diarrhea, and nausea. However, due to its selectivity for mutant EGFR, these side effects are generally less severe compared to earlier generation EGFR inhibitors.
Regulatory Status[edit | edit source]
Lazertinib has been approved for use in South Korea under the trade name Leclaza. It is currently undergoing further clinical trials to expand its indications and to gain approval in other countries.
Also see[edit | edit source]
- Epidermal growth factor receptor
- Tyrosine kinase inhibitor
- Non-small cell lung cancer
- EGFR T790M mutation
- Yuhan Corporation
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
